Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Quality Of Evidence Used By FDA To Approve New Drugs Varies Widely

As the FDA seeks to approve drugs not only more quickly but also accommodate a growing clamor to exhibit more flexibility for endorsing therapies for life-threatening diseases, a curious wrinkle has emerged – there is a wide variation in the quality of underlying evidence used for approvals.

Published
22 January 2014
From
Forbes
ViiV Healthcare's new HIV medicine Tivicay™ (dolutegravir) is approved in Europe

ViiV Healthcare today announced that the European Commission has approved Tivicay™ (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age.

Published
21 January 2014
From
ViiV Healthcare press release
NIH-created toxin can kill HIV-infected cells that persist despite treatment

A team including University of North Carolina and NIH scientists has demonstrated in a mouse model that an HIV-specific poison can kill cells in which the virus is actively reproducing despite antiretroviral therapy. According to the researchers, such a targeted poison could complement antiretroviral therapy, which dramatically reduces the replication of HIV in infected cells but does not eliminate them.

Published
10 January 2014
From
Eurekalert Medicine & Health
Merck Receives FDA Approval for ISENTRESS(R) (raltegravir) for Pediatric Oral Suspension

The oral suspension may be used in patients as young as four weeks of age, weighing at least 3 kg to less than 20 kg. The safety and efficacy of ISENTRESS have not been established in infants less than four weeks of age. Formulations of ISENTRESS for specific populations now include oral suspension, chewable tablets and film-coated tablets.

Published
09 January 2014
From
Wall Street Journal
Vertex's VX-765 holds promise for HIV treatment

In a recent report in the journal Science researchers at University of California, San Francisco and the Gladstone Institute of Virology and Immunology found that most CD4 T-cells aren't killed by the HIV virus directly, but by the body's cellular "suicide response" via a protein called caspase-1 (or interleukin-1 converting enzyme) and stopping this process prevents the progression of HIV to AIDS. What's more, the researchers showed that this suicide process is specifically inhibited by Vertex Pharmaceutical's caspase-1 inhibitor VX-765.

Published
07 January 2014
From
Motley Fool
New anti-HIV drug target identified

University of Minnesota researchers have discovered a first-of-its-kind series of compounds possessing anti-human immunodeficiency virus (HIV) activity. The compounds present a new target for potential HIV drug development and future treatment options.

Published
19 December 2013
From
Medical Xpress
Lupin launches HIV drug in the US

Drug major Lupin on Wednesday said it has launched the generic version of ViiV Healthcare’s (ViiV) Trizivir tablets in the US market with 180-days of marketing exclusivity.

Published
19 December 2013
From
The Hindu
U.S. FDA Approves Gilead’s Once-Daily Single Tablet HIV-1 Regimen Complera® for Patients Switching from a Stable Regimen

European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union.

Published
16 December 2013
From
Gilead press release
Sangamo BioSciences Presents Clinical Data From Key SB-728-T HIV Studies: Proof Of Concept For Ongoing Sustained Functional Control Of HIV Viral Load

Sangamo's Phase 1 data suggested that if a threshold level of engraftment of SB-728-T was achieved, specifically of CD4 cells fully protected from HIV entry by zinc finger nuclease (ZFN)-mediated modification of both CCR5 genes (biallelic modification), then functional control of HIV infection may be possible.

Published
10 December 2013
From
Sangamo Biosciences press release
Tivicay® (dolutegravir) receives positive CHMP opinion in Europe for the treatment of HIV

ViiV Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending marketing authorisation for Tivicay® (dolutegravir) for use in combination with other antiretroviral medicinal products for the treatment of HIV-infected adults and adolescents above 12 years of age.

Published
26 November 2013
From
European Medicines Agency

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.